UK Advertising Watchdog Bans LED Mask Ad for False Wrinkle Claims
The UK’s Advertising Standards Authority has banned an ad for a £299 LED mask, ruling its anti-wrinkle claims lacked sufficient evidence. Beauty Pie’s campaign is the latest to face scrutiny over exaggerated skincare promises.
The UK’s Advertising Standards Authority (ASA) has issued an enforcement notice barring Beauty Pie from publishing an advertisement for its £299 LED face mask, citing insufficient evidence to support claims it significantly reduces wrinkles. The watchdog’s decision, confirmed today, marks the first time an LED mask ad has been banned under strict new guidelines introduced in March targeting anti-aging product marketing.
Key Points
- ✅ ASA banned Beauty Pie’s £299 LED mask ad over unproven anti-wrinkle claims
- ⚡ First enforcement action under ASA’s 2024 anti-aging ad crackdown
- 💡 Consumers report mixed results from LED therapy devices despite high price tags
In its ruling, the ASA stated that Beauty Pie’s campaign—promoted across Instagram and the brand’s website—failed to provide robust clinical trials or peer-reviewed studies validating its efficacy. The watchdog demanded the ads be withdrawn immediately and not reused without substantiated evidence. Beauty Pie, which markets itself as a science-backed skincare brand, has not publicly responded to the ban.
Industry analysts say the ban underscores growing regulatory pressure on skincare brands leveraging LED technology. A 2023 survey by Which?, a consumer watchdog, found that 68% of LED mask users saw no measurable improvement in fine lines after three months of use. The ASA’s ruling follows a surge in complaints about misleading anti-aging claims, with 42 similar cases logged since January 2024.
| Aspect | Beauty Pie LED Mask | Industry Standard |
|---|---|---|
| Price | £299 | £89–£499 |
| Claimed Benefits | Wrinkle reduction, collagen boost | Temporary skin tone improvement |
| Regulatory Status | Banned in UK | Varies by country |
The ASA’s decision comes amid broader scrutiny of the £3.7 billion global LED skincare market, projected to grow 8.5% annually through 2030. Dermatologists warn that while low-level light therapy (LLLT) has shown promise in clinical settings, over-the-counter devices lack FDA clearance for wrinkle treatment in the US and similar certifications in the EU. Beauty Pie’s ad, which featured before-and-after images of a model’s “dramatically smoother” skin, was deemed misleading because it implied results were typical.
💡 Pro Tip
Consult a dermatologist before investing in LED masks—clinical-grade devices differ vastly from consumer models, and results vary widely based on skin type and usage frequency.
Beauty Pie, founded in 2016 by former Birchbox CEO Marcia Kilgore, has built a reputation on transparency in ingredient sourcing but now faces reputational damage. The banned ad campaign ran from February to April 2024, attracting 1.2 million views on social media. The ASA has given Beauty Pie until June 5 to comply with the ruling, after which non-compliance could trigger fines up to £100,000.
📋 By The Numbers
- 42 — Complaints about anti-aging ads filed with ASA since January 2024
- 68% — Share of LED mask users reporting no visible wrinkle improvement in Which? survey
- £100,000 — Maximum fine for non-compliance with ASA rulings
Legal experts predict the ASA’s stance will embolden further crackdowns on the beauty industry’s reliance on unverified claims. “The ASA is drawing a line in the sand,” said corporate lawyer Daniel Reeves. “Brands can no longer hide behind vague testimonials or before-and-after photos without hard data.” The watchdog has also flagged concerns about influencer partnerships, citing lack of disclosure in 18% of cases reviewed this year.
- June 5, 2024 — Deadline for Beauty Pie to remove all banned ads
- Q3 2024 — ASA to review Beauty Pie’s revised claims, if submitted
- 2025 — Potential expansion of enforcement to other LED mask brands
For consumers, the ban serves as a cautionary tale about the booming $15 billion anti-aging market. While LED therapy shows potential in dermatology clinics, the ASA’s ruling highlights the gap between clinical promise and mass-market reality. Beauty Pie’s case may set a precedent, forcing brands to invest in rigorous trials or risk regulatory action.